A PHASE III RANDOMIZED TRIAL OF FOLFOXIRI + BEVACIZUMAB VERSUS FOLFIRI + BEVACIZUMAB AS FIRST- LINE TREATMENT FOR METASTATIC COLORECTAL CANCER

Trial Profile

A PHASE III RANDOMIZED TRIAL OF FOLFOXIRI + BEVACIZUMAB VERSUS FOLFIRI + BEVACIZUMAB AS FIRST- LINE TREATMENT FOR METASTATIC COLORECTAL CANCER

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Jan 2018

At a glance

  • Drugs Bevacizumab (Primary) ; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms TRIBE
  • Most Recent Events

    • 08 Jan 2018 Results assessing the prognostic and predictive role of NLR in metastatic colorectal cancer patients treated with first-line FOLFOXIRI plus bevacizumab or FOLFIRI plus bevacizumab, were published in the Annals of Oncology.
    • 06 Jun 2017 Results (n=482) of pooled analysis of TRIBE and MOMA studies presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 24 Mar 2017 Results assessing Autophagy-related polymorphisms as predictor of bevacizumab-mediated toxicity in patients from two randomised trials (TRIBE and FIRE-3; n=657), published in the European Journal of Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top